(Q37752231)

English

Methicillin-resistant Staphylococcus aureus in community-acquired and health care-associated pneumonia: incidence, diagnosis, and treatment options

scientific article published on February 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

1 reference

Europe PubMed Central

Methicillin-resistant Staphylococcus aureus in community-acquired and health care-associated pneumonia: incidence, diagnosis, and treatment options (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

methicillin-resistant Staphylococcus aureus

0 references

0 references

Staphylococcus aureus

1 reference

based on heuristic

inferred from title

author name string

Nathan Dean

1

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

language of work or name

0 references

publication date

1 February 2010

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Hospital Practice

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

38

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

7-15

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Antimicrobial-resistant Streptococcus pneumoniae: trends and management

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Health care-associated pneumonia: identification and initial management in the ED.

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

The role of MRSA in healthcare-associated pneumonia

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Health care-associated pneumonia and community-acquired pneumonia: a single-center experience

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Methicillin-resistant Staphylococcus aureus disease in three communities

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia.

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Methicillin-resistant Staphylococcus aureus at Boston City Hospital. Bacteriologic and epidemiologic observations

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection.

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Genotypic and phenotypic relationships among methicillin-resistant Staphylococcus aureus from three multicentre bacteraemia studies

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Linezolid: a review of safety and tolerability

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Clinical characteristics of linezolid-resistant Staphylococcus aureus infections.

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008.

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Factors Predicting Mortality in Necrotizing Community-Acquired Pneumonia Caused by Staphylococcus aureus Containing Panton-Valentine Leukocidin

1 reference

https://api.crossref.org/works/10.3810%2FHP.2010.02.274

21 January 2018

Identifiers

10.3810/HP.2010.02.274

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37752231&oldid=1726890267"